Literature DB >> 19559498

Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs.

K W Jordan1, C B Adkins, L Su, E F Halpern, E J Mark, D C Christiani, L L Cheng.   

Abstract

The prospect of establishing serum metabolomic profiles offers great clinical significance for its potential to detect human lung cancers at clinically asymptomatic stages. Patients with suspicious serum metabolomic profiles may undergo advanced radiological tests that are too expensive to be employed as screening tools for the mass population. As the first step to establishing such profiles, this study investigates correlations between tissue and serum metabolomic profiles for squamous cell carcinoma (SCC) and adenocarcinoma (AC) in the lungs of humans. Tissue and serum paired samples from 14 patients (five SCCs and nine ACs), and seven serum samples from healthy controls were analyzed with high-resolution magic angle spinning proton magnetic resonance spectroscopy (HRMAS (1)HMRS). Tissue samples were subjected to quantitative histological pathology analyses after MRS. Based on pathology results, tissue metabolomic profiles for the evaluated cancer types were established using principal component and canonical analyses on measurable metabolites. The parameters used to construct tissue cancer profiles were then tested with serum spectroscopic results for their ability to differentiate between cancer types and identify cancer from controls. In addition, serum spectroscopic results were also analyzed independent of tissue data. Our results strongly indicate the potential of serum MR spectroscopy to achieve the task of differentiating between the tested human lung cancer types and from controls. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19559498      PMCID: PMC2834857          DOI: 10.1016/j.lungcan.2009.05.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics.

Authors:  Melissa A Burns; Wenlei He; Chin-Lee Wu; Leo L Cheng
Journal:  Technol Cancer Res Treat       Date:  2004-12

2.  Experimental protocol for clinical analysis of cerebrospinal fluid by high resolution proton magnetic resonance spectroscopy.

Authors:  S Maillet; J Vion-Dury; S Confort-Gouny; F Nicoli; N W Lutz; P Viout; P J Cozzone
Journal:  Brain Res Brain Res Protoc       Date:  1998-11

3.  FDG PET measurement of the proliferative potential of non-small cell lung cancer.

Authors:  K Higashi; Y Ueda; M Yagishita; Y Arisaka; A Sakurai; M Oguchi; H Seki; Y Nambu; H Tonami; I Yamamoto
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

4.  Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy.

Authors:  Leo L Cheng; Melissa A Burns; Jennifer L Taylor; Wenlei He; Elkan F Halpern; W Scott McDougal; Chin-Lee Wu
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.

Authors:  R J Hicks; V Kalff; M P MacManus; R E Ware; A Hogg; A F McKenzie; J P Matthews; D L Ball
Journal:  J Nucl Med       Date:  2001-11       Impact factor: 10.057

6.  FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features.

Authors:  K Higashi; Y Ueda; K Ayabe; A Sakurai; H Seki; Y Nambu; M Oguchi; H Shikata; S Taki; H Tonami; S Katsuda; I Yamamoto
Journal:  Nucl Med Commun       Date:  2000-08       Impact factor: 1.690

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

Review 8.  Value of whole-body FDG PET in management of lung cancer.

Authors:  Kotaro Higashi; Ichiro Matsunari; Yoshimichi Ueda; Ryosuke Ikeda; Jianfei Guo; Manabu Oguchi; Hisao Tonami; Itaru Yamamoto
Journal:  Ann Nucl Med       Date:  2003-02       Impact factor: 2.668

Review 9.  PET in lung cancer.

Authors:  R E Coleman
Journal:  J Nucl Med       Date:  1999-05       Impact factor: 10.057

10.  In vitro proton magnetic resonance spectroscopic lactate and choline measurements, 18F-FDG uptake, and prognosis in patients with lung adenocarcinoma.

Authors:  JianFei Guo; Kotaro Higashi; Hajime Yokota; Yosinobu Nagao; Yoshimichi Ueda; Yuko Kodama; Manabu Oguchi; Suzuka Taki; Hisao Tonami; Itaru Yamamoto
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

  10 in total
  24 in total

1.  Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer.

Authors:  Peter J Mazzone; Xiao-Feng Wang; Yaomin Xu; Tarek Mekhail; Mary C Beukemann; Jie Na; Jonathan W Kemling; Kenneth S Suslick; Madhu Sasidhar
Journal:  J Thorac Oncol       Date:  2012-01       Impact factor: 15.609

2.  Metabolic signatures of four major histological types of lung cancer cells.

Authors:  Swee Ling Lim; Zhunan Jia; Yonghai Lu; Hui Zhang; Cheng Teng Ng; Boon Huat Bay; Han Ming Shen; Choon Nam Ong
Journal:  Metabolomics       Date:  2018-08-31       Impact factor: 4.290

3.  A combined chemometric and quantitative NMR analysis of HIV/AIDS serum discloses metabolic alterations associated with disease status.

Authors:  Tracy R McKnight; Hikari A I Yoshihara; Lungile J Sitole; Jeffery N Martin; Francois Steffens; Debra Meyer
Journal:  Mol Biosyst       Date:  2014-11

4.  Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices.

Authors:  Sandra L Taylor; L Renee Ruhaak; Karen Kelly; Robert H Weiss; Kyoungmi Kim
Journal:  Brief Bioinform       Date:  2017-03-01       Impact factor: 11.622

5.  Multivariate two-part statistics for analysis of correlated mass spectrometry data from multiple biological specimens.

Authors:  Sandra L Taylor; L Renee Ruhaak; Robert H Weiss; Karen Kelly; Kyoungmi Kim
Journal:  Bioinformatics       Date:  2016-09-04       Impact factor: 6.937

Review 6.  Applications of high-resolution magic angle spinning MRS in biomedical studies II-Human diseases.

Authors:  Christopher Dietz; Felix Ehret; Francesco Palmas; Lindsey A Vandergrift; Yanni Jiang; Vanessa Schmitt; Vera Dufner; Piet Habbel; Johannes Nowak; Leo L Cheng
Journal:  NMR Biomed       Date:  2017-09-15       Impact factor: 4.044

7.  Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.

Authors:  Jie Shen; Yuanqing Ye; David W Chang; Maosheng Huang; John V Heymach; Jack A Roth; Xifeng Wu; Hua Zhao
Journal:  Lung Cancer       Date:  2017-11-02       Impact factor: 5.705

8.  The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling.

Authors:  Chi-Pang Wen; Fanmao Zhang; Dong Liang; Christopher Wen; Jian Gu; Heath Skinner; Wong-Ho Chow; Yuanqing Ye; Xia Pu; Michelle A T Hildebrandt; Maosheng Huang; Chien-Hua Chen; Chao Agnes Hsiung; Min Kuang Tsai; Chwen Keng Tsao; Scott M Lippman; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

9.  Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours?

Authors:  Iola F Duarte; Cláudia M Rocha; António S Barros; Ana M Gil; Brian J Goodfellow; Isabel M Carreira; João Bernardo; Ana Gomes; Vitor Sousa; Lina Carvalho
Journal:  Virchows Arch       Date:  2010-10-13       Impact factor: 4.064

Review 10.  Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Anthony J Alberg; Malcolm V Brock; Jean G Ford; Jonathan M Samet; Simon D Spivack
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.